**4.4 Teva's overall performance**

Since the end of 2015, Teva's shares are down by 64%, which has erased more than \$40 billion in market capitalization [18]. The company's worsening performance led to a wave of layoffs. Teva cut 14,000 jobs worldwide, which was more than 25 percent of the company's international workforce. According to Teva, it plans to lay off 1,750 employees, and that's just the beginning [19]. The layoffs will occur as a result of the closure or sale of a significant number of R&D sites, headquarters, offices, and a number of the company's geographical divisions will also be reduced.

By the end of 2017, Teva closed or sold six plants. This was followed by the closure of another nine plants in 2018.

The company's two plants in Jerusalem, which employed 1,100 employees, have been closed, the factory in Kiryat Shmona sold, the R&D center in Netanya, which employed 350, people has also closed as of 2019 [20].

In addition, Teva ceased operations at the global logistics center S.L.A. from the Shoham Industrial Area, even though it employed 700 people [21].

While on the one hand, the reduction plan raised the value of the stock by creating the illusion of improvement, it damaged employee and customer trust and further contributed to the deterioration of the company's shares.

In 2019, Teva's total revenue fell by 8% to \$16.9 million, which was a decrease of 8% as compared to 2018. This decline was mainly due to various reasons like the generic competition to COPAXONE®, a decline in revenues from U.S. generics business, BENDEKA®/TREANDA®, and Japan. However, this decline was partially offset by higher revenues from AUSTEDO, AJOVY, and QVAR® in the United States. COPAXONE® accounted for 11% of Teva's North America revenue from October to November 2019 [22].
